FoxO1 inhibition decreases CLL cell viability alone and more potently with BCR inhibition and blocks CLL proliferation induced by T cell signals (a combination of CD40L, IL-4 and IL-21). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.